Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses

Journal of the American Academy of Dermatology

Volumn 68, Issue 5, 2013, Pages 863-865

  Dommasch, Erica D ^a   Troxel, Andrea B ^b   Gelfand, Joel M ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CI; confidence interval; FDA; Food and Drug Administration; IL; interleukin; MACE; major adverse cardiovascular event; odds ratio; OR; randomized controlled trial; RCT

Indexed keywords

BRIAKINUMAB; ROSIGLITAZONE;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FOLLOW UP; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; NOTE; PRIORITY JOURNAL; PSORIASIS;

EID: 84876370997     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.01.011     Document Type: Editorial

References (18)

1. Petrou I. Systemic medications for psoriasis therapy must be prescribed with caution. Dermatology Times: Modern Medicine; 2011. http://www. modernmedicine.com/modernmedicine/Modern+Medicine+Now/Systemic-medications-for- psoriasis-therapy-must-be/ArticleStandard/Article/detail/717839. Accessed February 26, 2012.
2. T. Tzellos, A. Kyrgidis, and C.C. Zouboulis Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials J Eur Acad of Dermatol Venereol 2012:Mar 8 [Epub ahead of print]
3. C. Ryan, C.L. Leonardi, J.G. Krueger, A.B. Kimball, B.E. Strober, and K.B. Gordon Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials JAMA 306 2011 864 871
4. G.A. Diamond, L. Bax, and S. Kaul Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Ann Intern Med 147 2007 578 581
5. A.V. Hernandez, E. Walker, J.P.A. Ioannidis, and M.W. Kattan Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone Am Heart J 156 2008 23 30
6. M.J. Bradburn, J.J. Deeks, J.A. Berlin, and A. Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
7. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
8. E.D. Dommasch, K. Abuabara, D.B. Shin, J. Nguyen, A.B. Troxel, and J.M. Gelfand The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials J Am Acad Dermatol 64 2011 1035 1050
9. J.M. Gelfand Pharmacovigilance: Verifying that drugs remain safe S.E. Wolverton, Comprehensive dermatologic drug therapy 2007 Elsevier Philadelphia 1017 1026
10. O. Ahlehoff, G.H. Gislason, M. Charlot, C.H. Jørgensen, J. Lindhardsen, and J.B. Olesen Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study J Intern Med 270 2011 147 157
11. J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, and X. Wang The risk of stroke in patients with psoriasis J Invest Dermatol 129 2009 2411 2418
12. W.Q. Li, J.L. Han, J.E. Manson, E.B. Rimm, K.M. Rexrode, G.C. Curhan, and A.A. Qureshi Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study Br J Dermatol 166 2012 811 818
13. M.A. Weinstock, S.F. Bingham, R.A. Lew, R. Hall, D. Eilers, and R. Kirsner Topical tretinoin therapy and all-cause mortality Arch Dermatol 145 2009 18 24
14. A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, and H. Sofen Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study J Eur Acad Dermatol Venereol 2012 Dec 20 [Epub ahead of print]
15. A. Gottlieb, A. Menter, A. Mendelsohn, Y.-K. Shen, S. Li, and C. Guzzo Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial Lancet 373 2009 633 640
16. I.B. McInnes, A. Kavanaugh, A.B. Gottlieb, L. Puig, P. Rahman, and C. Ritchlin Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I Study Ann Rheum Dis 71 Suppl 3 2012 107
17. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, and S. Katz A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
18. W.J. Sandborn, C. Gasink, L.-L. Gao, M.A. Blank, J. Johanns, and C. Guzzo Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 2012 1519 1528